QT Imaging Holdings, Inc. · NASDAQ:QTI
QT Imaging — Investor Presentation (November 2026)
38 slides from QT Imaging's investor presentation, Nov 12, 2026
Slide 1: Quantitative Transmission Imaging Breast Acoustic CT Scanner
Quantitative Transmission Imaging Breast Acoustic CT™ Scanner November 2026 NASDAQ:QTI Copyright ©2026 QT Imaging, Inc. All Rights Reserved.
Slide 2: Disclaimer: About This Presentation
2 Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only. The information contained herein does not purport to be all-inclusive and neither QT Imaging Holdings, Inc. (the “Company”, “QT Imaging Holdings”, “QTI”), nor its respec
Slide 3: Disclaimer: Forward Looking Statements
3 Disclaimer FORWARD LOOKING STATEMENTS Certain statements included in this Presentation that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements genera
Slide 4: Our Mission: Transforming Breast Health For Every Woman
4 Our Mission Transforming Breast Health For Every Woman At QT Imaging, we are redefining what’s possible in breast imaging - delivering safe, high-resolution, and cost-effective solutions where traditional technologies fall short. Our goal is to replace outdated breast imaging workflows with the fi
Slide 5: QT Imaging Transformation 2012-2026
5 $18M from NIH to develop supplemental imaging modality to resolve dense breasts 2012-2026 QT Imaging Transformation Company founded by John Klock, MD 2012 FDA Clearance 2017 Raise $18M PIPE Oct 2025 Approval of Category III CPT Billing Code Oct 2026 QTI becomes public on NASDAQ Mar 2024 $10M Under
Slide 6: The Pain and Why QT Imaging
6 The Pain and Why QT Imaging The Pain Why QT Imaging Copyright ©2026 QT Imaging, Inc. All Rights Reserved • Mammography misses cancers in dense breasts / painful procedure • MRI is expensive / slow / uncomfortable / contrast injection • Ultrasound is operator dependent • Workflow is fragmented • Hi
Slide 7: Breast Cancer Screening Matrix: QT Imaging Sweet Spot
7 Breast Cancer Screening Matrix QT Imaging Sweet Spot Risk Category (Tyrer-Cuzick Lifetime Risk) + Breast Density Typical Risk Profile Description < 40 Years ≥ 40 Years Low Risk (<12%) (~20–30% of women) No first-degree relatives with breast cancer No known pathogenic mutations No prior chest radia
Slide 8: QT Imaging Value Proposition
8 QT Imaging Value Proposition • One-stop-shop supplemental + diagnostic imaging • No radiation, no compression, no contrast • Low recall, less anxiety • Operator independent • One test – multiple results (MRI like Imaging) • Calcium visualization, Density, Doubling, Cyst/Solid, Implant • Biomarkers
Slide 9: Medicare Reimbursement: A Catalyst for Commercial Growth
9Copyright ©2026 QT Imaging, Inc. All Rights Reserved. • Accelerate Scanner Adoption Payment visibility reduces a key financial barrier and strengthens the business case for hospitals and outpatient imaging providers. • Expand Recurring Revenue Higher examination volume creates opportunities for QTI
Slide 10: Reimbursement Strategy: Three Clinical Growth Opportunities
10Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Reimbursement Strategy Three Clinical Growth Opportunities Supplemental Imaging for Dense Breasts Radiation-free, contrast-free adjunctive imaging for women with dense breast tissue. Re-engaging Underscreened Women Potential pathway to bring wo
Slide 11: Primary Screening Pathway
11 Primary Screening Today’s Challenge: Multi-step, patient anxiety and attrition prone process with high number of unnecessary biopsies Accurate Imaging for Dense Breasts Breast Density Confirmation Supplemental Screening QT Imaging Solution: Single step (Supplemental + Dx) patient friendly process
Slide 12: Discovering Tumors Not Seen in Dense Breasts
Discovering Tumors Not Seen in Dense Breasts (C/D) HHUS • NegMammo • Neg MRI QTscan Copyright ©2026 QT Imaging, Inc. All Rights Reserved. QTscan to simplify the breast imaging pathway by combining supplemental and diagnostic imaging in a single, patient-friendly examination, reducing unnecessary fol
Slide 13: Monitoring Response to Neoadjuvant Chemotherapy
13Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Monitoring Response to Neoadjuvant Chemotherapy • QT Imaging is undergoing trials to monitor tumor response to neoadjuvant chemotherapy to detect early tumor response and guide treatment management QT Imaging’s quantitative biomarkers offer the
Slide 14: Discovering Cancers in Women Without Screening
14 Discovering Cancers in Women Without Screening QT imaging has demon- strated that it can find breast cancers in patients who did not want mammography due to concerns with radiation, pain, or modesty. Copyright ©2026 QT Imaging, Inc. All Rights Reserved CORONAL AXIAL SAGITAL QTscan offers women wh
Slide 15: Our Technology and Product
15 Our Technology and Product • FDA-cleared, patent protected breast imaging modality • Pain free, safe, no radiation or contrast • Inherently 3D quantitative, imaging modality, thus it’s high resolution, similar to MRI • Two independent sources of information: − CT-like configuration with ultrasoun
Slide 16: Why Biomarkers Matter for QT Imaging
16 What’s Next Why Biomarkers Matter for QT Imaging? Clinical Utility Biomarkers allow QT Imaging to move beyond detection toward diagnostic and prognostic precision through quantitative imaging: • Early detection of malignancy using defined quantitative thresholds • Therapy monitoring such as patho
Slide 17: QT Imaging Acoustic Biomarkers Roadmap
QT Imaging Acoustic Biomarkers Roadmap Current vs Future Copyright ©2026 QT Imaging, Inc. All Rights Reserved Biomarker Domain: Physical Metric Today (SW 4.5.2) Future (SW 4.6.0) Beyond (SW 4.6.0) Speed of Sound (SoS) Velocity (m/s) Tissue differentiation (<1% var) Ongoing improvements Real-time AI
Slide 18: Optimized Patient Experience
18 Optimized Patient Experience • No ionizing radiation. Acoustic source only • No breast compression and associated discomfort • 10-12 minutes per breast exam time • Quiet and comfortable (compared to MRI – claustrophobia, coil pressure, noise, lengthy exams) • No contrast injection or associated r
Slide 19: Our Market, Why Now, and How It Fits In
Our Market, Why Now, and How It Fits In
Slide 20: QT Imaging Technology Has the Opportunity to Transform the Breast Imaging Market
20 (1) https://www.futuremarketinsights.com/reports/automated-breast-ultrasound-system-market (2) https://www.grandviewresearch.com/industry-analysis/breast-imaging-equipment-market $5.45B for 2024 with 8.9% CAGR. (3) https://www.archivemarketresearch.com/reports/breast-cancer-biomarkers-316622 (4)
Slide 21: FDA Recognized Importance of Breast Density; Three Tailwinds
21Copyright ©2026 QT Imaging, Inc. All Rights Reserved. The FDA Has Recognized the Importance of Breast Density in Breast Cancer Screening Radiology is the leading specialty for clinical AI adoption • ~30 to 48% of radiologists report active clinical AI use; adoption continues to accelerate across i
Slide 22: Validation
%. -> QT IMAGING Validation
Slide 23: Clinical Advisory Board
23 Clinical Advisory Board Copyright ©2026 QT Imaging, Inc. All Rights Reserved Mary Yamashita, MD Barry Roseman, MD, FACS John Tentinger, MD Section Chief of Breast Imaging at USC’s Keck School of Medicine and a longtime leader in breast cancer screening research, Dr. Yamashita advises QT Imaging o
Slide 24: Growing Global Validation
24 Growing Global Validation • Existing FDA clearance to offer an imaging modality for all patients above 18 years old • Received Saudi Arabia, UAE, Israel, Bahrain, Qatar regulatory approvals. Working on CE mark regulatory • NIH $18M funding to generate a safe imaging modality for women with dense
Slide 25: Clinical Validation: Mayo Clinic QT Scan vs MRI
25 Clinical Validation Across Screening & Oncology Applications: Mayo Clinic – QT Scan vs MRI • Mayo Clinic prospective feasibility study: 26 high-risk women comparing QT Imaging (QT Scan) with breast MRI for supplemental screening • Strong breast-level agreement with MRI: binary agreement between Q
Slide 26: Clinical Validation: Sunnybrook Cancer Center QT Scan vs MRI
26 MRI Clinical Validation Across Screening & Oncology Applications: Sunnybrook Cancer Center – QT Scan vs MRI • NIH/NCI-funded, to prove QT Imaging as imaging modality for early monitoring of breast cancer response to neoadjuvant chemotherapy (NAC) • Major oncology need: − treatment response that c
Slide 27: Multi-site Repeatability & Reproducibility Study
27Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Multi-site Repeatability & Reproducibility Study • Multi-site study (2 sites, 5 patients/site, 5 scans each) confirms QT Imaging's quantitative biomarkers are highly reproducible within and across scanners • Speed of Sound (SoS), our core tissu
Slide 28: Business Model, Partnerships & Financial Trajectory
Business Model, Partnerships & Financial Trajectory
Slide 29: Business Model: HW + SaaS + AI Diagnostic Layer
29 Business Model HW+ SaaS +AI Diagnostic Layer Business Model: • Hardware sale (scanner): upfront revenue • SaaS platform: recurring revenue • AI diagnostic layer: higher margin Radiology Cloud SaaS Platform Referring MD Hardware gets us in the door. Software builds the company. Copyright ©2026 QT
Slide 30: QTI Precision Pathway – Cloud SaaS Platform
30 QTI Precision Pathway – Cloud SaaS Platform Core Operational Advanced Enterprise System software updates Long term technology relevance Collaboration & data sharing Quantitated biomarkers Automated analysis Precision reporting Multiuser access Enterprise collaboration Scanner Evergreen QTI Precis
Slide 31: Planned Evolution to Hybrid Commercial Model
31 Planned Evolution to Hybrid Commercial Model as Scale Increases Commercial strategy balances capital efficiency today with increasing control and margin expansion over time. 2024-2026 2027 and beyond Distributor Led Hybrid Model • Broad market coverage • Capital efficient • Rapid deployment • Dir
Slide 32: Business Partnerships Today
32Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Business Partnerships Today Under Distribution Agreement with NXC Imaging (Subsidiary of Canon Medical Systems) for U.S. market Under Distribution Agreement with Gulf Medical for Kingdom of Saudi Arabia (KSA) market Under Distribution Agreement
Slide 33: Premier Recognition & National Hospital Access
33Copyright ©2026 QT Imaging, Inc. All Rights Reserved. Premier Recognition & National Hospital Access • Innovation recognition paired with a streamlined national purchasing pathway Nearly 4,400 U.S. Hospitals & Health Systems 2026 Breakthroughs Innovation Award Recognized by Premier for innovative,
Slide 34: Financial Trajectory
34 Financial Trajectory Copyright ©2026 QT Imaging, Inc. All Rights Reserved FY-2024A FY-2025A FY-2026E CAGR 2024A - 2026E Revenue ($k) $4,879 $18,926 $34,347 Growth % 287.91% 81.1% 165.3% 4 4 2 2 6 8 9 17 13 15 15 0 2 4 6 8 10 12 14 16 18 $- $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 $7.00 $8.00 $9.00 Q1
Slide 35: Financial Trajectory: Unit Economics per Scanner
35 Financial Trajectory QT Imaging is scaling a commercial business Copyright ©2026 QT Imaging, Inc. All Rights Reserved $407 $473 $505 $(613) $(88) $(58) 54% 45% 43% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% $(700) $(600) $(500) $(400) $(300) $(200) $(100) $- $100 $200 $300 $400 $500 $600 F
Slide 36: Manufacturing Capacity, Quality, and Compliance
36 Manufacturing Capacity, Quality, and Compliance • Expanded manufacturing capacity while improving operating efficiency − 22,000-square-foot headquarters and manufacturing facility − The expanded facility provides more than 2.5x the operational space of the current location while reducing lease co
Slide 37: QT Imaging Positioned for Accelerated Commercial Growth
37 QT Imaging Positioned for Accelerated Commercial Growth • Strong Revenue Growth: Revenue increased from $4.9M in 2024 to $18.9M in 2025, with $34.3M projected for 2026, representing approximately 81% year-over-year growth • Major Medicare Reimbursement Milestone: Dedicated CPT billing code 1079T
Slide 38: Thank You!
%. -> QT IMAGING Thank You!
QT Imaging Holdings — Investor Presentation (November 2026) on 6ix